scholarly journals The effect of cold hat use on chemotherapy-induced hair loss in breast cancer patients: An experimental study in Tehran

2020 ◽  
Vol 13 (1) ◽  
pp. 17-23
Author(s):  
Zahra Mirbagher ◽  
Tahereh Nasrabadi ◽  
Sepideh Nasrollah ◽  
◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Experimental Study ◽  
Cancer Patients ◽  
Hair Loss ◽  
Breast Cancer Patients

Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience

2019 ◽  
Vol 14 (1) ◽  
pp. 66-71 ◽  
Author(s):  
Tiziana Prochilo ◽  
Alessandra Huscher ◽  
Federica Andreis ◽  
Mara Mirandola ◽  
Elisabetta Zaina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hair Loss ◽  
Depression Scale ◽  
Hair Follicles ◽  
Common Side Effect ◽  
Scalp Cooling ◽  
Breast Cancer Patients ◽  
Cooling Device ◽  
End Of Treatment

Background: The most effective agents in the treatment of breast cancer have a common side effect, the hair loss. Some studies reported a reduction of hair loss with the use of the scalp cooling device. Indeed, it decreases the drug accumulation in the hair follicles. We report our preliminary experience with a scalp cooling device in reducing chemotherapy-induced alopecia and related distress in breast cancer patients undergoing adjuvant chemotherapy. </P><P> Methods: Hair loss grading and treatment tolerability were evaluated during chemotherapy every 21 days and 3 weeks after the last cycle of chemotherapy via Dean’s scale by patients and operators and a comfort analogic scale by patients. We administered the Hospital Anxiety and Depression Scale questionnaire at the baseline and at the end of treatment to assess the distress related to chemotherapy- induced alopecia. Results: Among the 46 patients identified, 27 accepted the device. The eligible chemotherapy regimens included docetaxel+cyclophosphamide (TC), doxorubicin+cyclophosphamide (AC) and paclitaxel (P) weekly+trastuzumab (T). 24 pts (89%) completed the treatment; 3 pts (11%) treated with AC prematurely interrupted use of the scalp-cooling device due to inefficacy. After the last cycle of chemotherapy, the number of patient who perceived a HL < grade 2 was 16 (59%). The hair retention reported by operators has been higher (78%). 81.5% of patients well tolerated the treatment. Conclusion: In our study, the scalp-cooling device reduced chemotherapy-induced alopecia in taxane- based chemotherapy. Furthermore, it suggests a discordance in hair loss perception between patients and operators.

scholarly journals Application of a domicile-based exercise program for shoulder rehabilitation after breast cancer surgery

2012 ◽  
Vol 20 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Eliana Louzada Petito ◽  
Afonso Celso Pinto Nazário ◽  
Simone Elias Martinelli ◽  
Gil Facina ◽  
Maria Gaby Rivero De Gutiérrez
Keyword(s):  
Breast Cancer ◽  
Experimental Study ◽  
Cancer Patients ◽  
Preoperative Evaluation ◽  
Exercise Program ◽  
Breast Cancer Surgery ◽  
Breast Cancer Patients ◽  
Quasi Experimental ◽  
Study Population

The aim of this study was to evaluate the effectiveness of an exercise program for the recuperation of the range of motion (ROM) of the shoulder. This is a quasi-experimental study developed at the Mastology Outpatient Clinic of the Federal University of São Paulo - Brazil, from August 2006 to June 2008, with 64 breast cancer patients undergoing surgery. The intervention consisted of: preoperative evaluation of the ROM, verbal and written guidance, demonstration and implementation of the exercises and revaluation at the outpatient follow-up appointments until the 105th postoperative day (PO). From the 7th PO a significant increase was observed in the ROM, which continued until the 105th PO. The minimum time for recovery was 105 days for the women undergoing mastectomy, and 75 days for those undergoing quadrantectomy. There was satisfactory adherence of 78.6% of the women. The domicile program was effective for the recovery of ROM in the study population, benefiting women who can not attend a presential program.

Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy

2002 ◽  
Vol 10 (7) ◽  
pp. 529-537 ◽  
Author(s):  
Christel Protière ◽  
Katrin Evans ◽  
Jacques Camerlo ◽  
Marie-Pierre d'Ingrado ◽  
Geneviève Macquart-Moulin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Hair Loss ◽  
Cooling System ◽  
Scalp Cooling ◽  
Breast Cancer Patients

P098 Scalp cooling system to prevent hair loss in breast cancer patients receiving chemotherapy

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S59 ◽  
Author(s):  
T. Kinoshita ◽  
K. Tamura ◽  
A. Hashimoto ◽  
T. Ogura ◽  
A. Hironaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hair Loss ◽  
Cooling System ◽  
Scalp Cooling ◽  
Breast Cancer Patients

Hair loss associated with aromatase inhibitor treatment among breast cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21619-e21619
Author(s):  
Lisa Gallicchio ◽  
Carla Calhoun ◽  
Kathy J. Helzlsouer
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Hair Loss ◽  
Side Effect ◽  
Common Side Effect ◽  
Breast Cancer Patients ◽  
Increased Risk

e21619 Background: Hair loss and thinning have been reported by breast cancer patients treated with aromatase inhibitors (AIs); these side effects are documented to be reasons that patients discontinue their AI therapy and have been shown to be associated with a decrease in quality of life. Despite this knowledge, there is a paucity of detailed data on hair changes over the course of AI therapy. The purpose of this study was to examine hair changes and risk factors for hair loss among breast cancer patients initiating aromatase inhibitor therapy and followed for one year. Methods: Data were analyzed from a cohort of 146 breast cancer patients initiating AI therapy and followed over the first year of their AI treatment. At baseline (prior to AI therapy) and at 1-year, a questionnaire was administered that ascertained data on demographics, health behaviors, and symptoms. Detailed hair loss questions, including those pertaining to family history and specific location of hair loss, were added during the study period when study staff noticed that hair loss and thinning were commonly being reported on the symptom checklist after initiation of AI therapy. Multivariable logistic regression analysis was conducted to examine factors related to AI-attributed hair loss. Results: Among the 86 breast cancer patients who completed the detailed hair loss survey at 1-year (mean age = 63y), 43% reported experiencing hair loss after the initiation of AI therapy. The most frequently reported time period of onset of the AI-attributed hair loss was between 3 and 6 months post-AI initiation (43.2%), with 67.6% of patients noting hair loss in the mid-scalp (top of head). Factors significantly associated with AI-related hair loss at 1-year were: hair loss prior to AI therapy, having a BMI > 30 kg/m2(odds ratio (OR) = 6.5), being a current smoker (OR = 7.8), and maternal history of hair loss or hair thinning (OR = 9.1). ORs were similar when patients with prior chemotherapy were excluded. Conclusions: Hair loss is a common side effect of AI therapy that can negatively affect a patient’s quality of life and potentially lead to treatment discontinuation. Treatment options for this AI-related side effect should be explored, especially for patients who are at increased risk.

Sign in / Sign up

Export Citation Format

Share Document